This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna Considers Divesting Its Non-Health Insurance Business
by Zacks Equity Research
Speculations ran rife that Cigna (CI) is on the lookout of a bidder for its non-health insurance arm to streamline in-house operations.
MetLife to Foray Into Pet Insurance Via PetFirst Acquisition
by Zacks Equity Research
MetLife (MET) to acquire PetFirst to enter the rapidly growing pet insurance market.
MetLife (MET) to Provide Estate Planning Via Willing Buyout
by Zacks Equity Research
MetLife (MET) agrees to acquire Willing and provide online estate planning services to its group customers.
Q3 Earnings Push Insurance ETFs Higher
by Sweta Killa
The Q3 earnings of insurance industry players had a positive impact on the related ETFs that saw smooth trading over the past month.
MetLife (MET) Q3 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
MetLife (MET) Q3 earnings suffer from high expenses, which offset revenue growth.
MetLife (MET) Lags Q3 Earnings Estimates
by Zacks Equity Research
MetLife (MET) delivered earnings and revenue surprises of -9.93% and 3.36%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for MetLife (MET)
by Zacks Equity Research
MetLife (MET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can MetLife (MET) Maintain Its Earnings Beat Streak in Q3?
by Sapna Bagaria
MetLife's (MET) Q3 earnings are likely to have gained from higher premiums and share buyback partly offset by lower investment income.
MetLife (MET) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
MetLife (MET) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why MetLife (MET) Could Beat Earnings Estimates Again
by Zacks Equity Research
MetLife (MET) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bleak Near-Term Outlook for Multiline Insurance Industry
by Tanuka De
The Multiline Insurance Industry should benefit from better pricing and a solid capital level. However, a declining rate environment is a concern.
Are You Looking for a High-Growth Dividend Stock? MetLife (MET) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
Has MetLife (MET) Outpaced Other Finance Stocks This Year?
by Zacks Equity Research
Is (MET) Outperforming Other Finance Stocks This Year?
Should Value Investors Buy MetLife (MET) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Marsh & McLennan Arm to Pilot Digital Placement Platform
by Zacks Equity Research
Marsh & McLennan's (MMC) Marsh subsidiary to pilot a blockchain-enabled digital platform to ease the insurance placement procedure.
Why Should You Retain CNO Financial (CNO) in Your Portfolio?
by Zacks Equity Research
Riding high on its strong revenue base and a solid capital position, CNO Financial (CNO) is expected to reap benefits for investors.
MetLife Suffers Due to Low Interest Rate, Eyes Recovery
by Zacks Equity Research
Low interest rates weigh on MetLife's (MET) investment income but various recovery measures help.
5 Low Price-to-Book Stocks to Increase Your Portfolio's Value
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Here's Why Hold Strategy is Apt for MGIC Investment (MTG)
by Zacks Equity Research
MGIC Investment (MTG) is poised to grow over the long term given its operational excellence and growth initiatives.
5 Buffett-Style Value Picks Boasting Impressive PEG Ratio
by Urmimala Biswas
While P/E alone fails to identify a true value stock, PEG helps find the intrinsic value of a stock.
MGIC Investment Records Solid Insurance in Force in August
by Zacks Equity Research
MGIC Investment's (MTG) August operating business statistics reflect improved insurancea in force and decline in delinquent inventory.
Why MetLife (MET) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
Here's Why You Should Add Amerisafe (AMSF) to Your Portfolio
by Zacks Equity Research
Amerisafe (AMSF) to benefit from niche presence in workers' compensation insurance and disciplined underwriting.
Here's Why You Should Invest in Radian Group (RDN) Stock Now
by Zacks Equity Research
Radian Group (RDN) is poised to grow over the long term given its operational excellence and growth initiatives.
Has MetLife (MET) Outpaced Other Finance Stocks This Year?
by Zacks Equity Research
Is (MET) Outperforming Other Finance Stocks This Year?